CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Deficiency of lysosomal TMEM175 in myeloid macrophages exerts anti-tumor immunity via inflammasome and cross-presentation pathway.
Deficiency of lysosomal TMEM175 in myeloid macrophages exerts anti-tumor immunity via inflammasome and cross-presentation pathway.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
发现更多靶点对于开发肿瘤治疗的替代干预措施至关重要。跨膜蛋白175(TMEM175)在神经退行性疾病中的作用已有报道,但其在肿瘤免疫监视中的功能尚不清楚。我们发现,巨噬细胞中TMEM175的条件性敲除通过促进肿瘤微环境(TME)中的抗肿瘤免疫来抑制肿瘤生长和转移,包括M1样极化升高、M2样极化降低,以及促进T细胞和NK 细胞(NKs)的募集和活化。这种抗肿瘤免疫被caspase-1抑制剂VX-765、抗IL-1β和抗IL-18所消除。Tmem175 -/- 骨髓来源巨噬细胞(BMDMs)表现出增强的肿瘤抗原交叉呈递,而IL-1β和IL-18进一步增强了这一效应。在Tmem175 -/- BMDMs中,肿瘤细胞碎片通过溶酶体膜通透化和组织蛋白酶B泄漏强烈引发NLRP3。最后,Tmem175 -/- 小鼠对抗PD-1治疗更为敏感。我们的工作表明TMEM175可能是免疫治疗的一个潜在靶点。
Discovering more targets is of great importance for developing alternative interventions for tumor therapy. The roles of transmembrane protein 175 (TMEM175) in neurodegeneration diseases have been reported, however its functions in tumor immune surveillance are not known.
We show that TMEM175 conditional knockout in macrophages inhibits the tumor growth and metastasis through promoting the anti-tumor immunity in the tumor microenvironment (TME), including elevated M1-like polarization, reduced M2-like polarization, and facilitated recruitment and activation of T cells and nature killer cells (NKs).
The anti-tumor immunity is abrogated by caspase-1 inhibitor VX-765, anti-IL-1β, and anti-IL-18. Tmem175 -/- bone marrow-derived macrophages (BMDMs) show enhanced tumor antigen cross-presentation that is further strengthened by IL-1β and IL-18. NLRP3 is robustly elicited in Tmem175 -/- BMDMs by the tumor cell debris through lysosomal permeabilization and cathepsin B leakage.
Finally, Tmem175 -/- mice are more responsive to anti-PD-1.
Our works implies TMEM175 to be a potential target for immunotherapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。